Silenseed is a clinical-stage biopharmaceutical company that is using a proprietary RNA interference strategy to develop cancer drugs and delivery systems designed to effectively penetrate and treat malignant solid tumors.The companys novel drugs, combined with the local drug eluter (LODER) delivery system, have the potential to become an effective treatment for solid tumor cancers.

Silenseed is focused on treatments for pancreatic cancer, prostate cancer, and certain brain cancers.Silenseed has completed a phase 2a clinical study for pancreatic cancer which showed promising results.